Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Also Read: Pfizer's Paxlovid Demonstrates Safety But ... that traditional medical records may overlook. Extended antiviral courses have precedent in other conditions like HIV and hepatitis C ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...

Pfizer estimates that it will rake in record-breaking earnings of more than $100 billion this year due to sales of its Covid-19 vaccine and antiviral pill to treat the virus, Daily Mail reported.

Pfizer's stock has plummeted due to declining ... However, in 2024 COVID-19 products together (Comirnaty and anti-viral Paxlovid) are expected to contribute only 16-17% to total sales (about ...